Discover 282 paid clinical trials in South Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
South Dakota offers a range of options for both healthy volunteers interested in paid clinical studies and individuals with specific health conditions. Major research hubs in Sioux Falls, Rapid City, and Aberdeen are currently recruiting participants, allowing access to groundbreaking treatments and advanced medical support.
Filter
1
Filter results
Results: 282
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
for
Ovarian Cancer
Location: Scarborough ME, Worcester MA, New York NY, Camden NJ,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07059845
Phase2, Recruiting
Featured
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
for
Obesity or Overweight
Location: Boston MA, Needham MA, New Haven CT, Quebec,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07351045
Phase3, Recruiting
Featured
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
for
Obesity or Overweight, Type 2 Diabetes Mellitus
Location: Quebec, Sherbrooke, Montreal, Morehead City NC,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07351058
Phase3, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
for
Parkinson's Disease
Location: Boston MA, New Haven CT, New York NY, Commack NY,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 50 - 70+
Code: NCT07174310
Phase3, Recruiting
Featured
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
for
Epithelial Ovarian Cancer, Fallopian Tube Cancer,
Location: Providence RI, New Haven CT, Lebanon NH, Bay Shore NY,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06890338
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Location: Burlington MA, East Greenwich RI, Framingham MA,
Sponsor: 89bio, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06419374
Phase3, Recruiting
Active & Responsive
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
for
Intestinal Neoplasms, Gastrointestinal Neoplasms,
Location: Topsham ME, Westbrook ME, Boston MA, Newton MA,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07222800
Phase3, Recruiting
Active & Responsive
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
for
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC,
Location: New York NY, Belleville NJ, Philadelphia PA, Newark DE,
Sponsor: Immuneering Corporation
Sex: All
Age: 18+
Code: NCT07562152
Phase3, Recruiting
Active & Responsive
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
for
Metastatic Dedifferentiated Liposarcoma,
Location: Boston MA, Waterford CT, Guilford CT, New Haven CT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06422806
Phase3, Recruiting
Active & Responsive
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Springfield MA, Saint Johnsbury VT, Lebanon NH,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05136196
Phase2, Recruiting
Active & Responsive
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
for
Recurrent Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Waterford CT, New Haven CT, Stony Brook NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT04671667
Phase2, Recruiting
Active & Responsive
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
for
Crohn's Disease
Location: Kentville, Boston MA, Providence RI, Levis,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 16 - 70+
Code: NCT06430801
Phase3, Recruiting
Active & Responsive
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Commack NY, Uniondale NY, Harrison NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06589804
Phase3, Recruiting
Active & Responsive
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
for
Moderate to Severe Chronic Obstructive Pulmonary Disease
Location: Greenacres City FL, Loxahatchee Groves FL, Miami FL,
Sponsor: Pfizer
Sex: All
Age: 35 - 70+
Code: NCT07363694
Phase2, Phase3, Recruiting
Active & Responsive
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention